Real-world benefit of nivolumab in a Canadian non-small-cell lung cancer cohort

R. A. Juergens, C. Mariano, J. Jolivet, N. Finn, J. Rothenstein, M. N. Reaume, A. Faghih, C. Labbé, S. Owen, F. A Shepherd, J. Villeneuve, F. Romeyer, F. Pettersson, C. Butts

Abstract


Background Nivolumab was the first immuno-oncology agent available for the treatment of lung cancer in Canada. In the present study, we evaluated the real-world benefit of nivolumab in Canadian patients with lung cancer.

Methods Patients included in the cohort were identified from a registry of patients treated through expanded access to nivolumab before and after Health Canada approval. Demographics were collected from the application forms. Outcome data for the duration of treatment and survival were collected retrospectively.

Results In contrast to the randomized clinical trial populations, our study cohort included patients who were older (median age: 66 years; range: 36–92 years) and who had an Eastern Cooperative Oncology Group performance status of 2 (8.9%). Despite the poorer-prognosis cohort, median overall survival was 12.0 months, which is comparable to the survival demonstrated in the randomized phase iii trials of nivolumab in lung cancer. Median time to treatment discontinuation was 3.45 months and was similar for all patient subgroups, including poorer-prognosis groups such as those with a performance status of 2, those 75 years of age and older, and those with brain metastases.

Conclusions Nivolumab given in a real-world clinical setting was associated with results similar to those reported in the phase iii clinical trial setting.


Keywords


Nivolumab; non-small-cell lung cancer; real-world data; duration of treatment; overall survival

Full Text:

PDF HTML


DOI: http://dx.doi.org/10.3747/co.25.4287






Copyright © 2019 Multimed Inc.
ISSN: 1198-0052 (Print) ISSN: 1718-7729 (Online)